JP2019537438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537438A5 JP2019537438A5 JP2019522850A JP2019522850A JP2019537438A5 JP 2019537438 A5 JP2019537438 A5 JP 2019537438A5 JP 2019522850 A JP2019522850 A JP 2019522850A JP 2019522850 A JP2019522850 A JP 2019522850A JP 2019537438 A5 JP2019537438 A5 JP 2019537438A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- residue
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 claims description 68
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 68
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 67
- 241000124008 Mammalia Species 0.000 claims description 56
- 239000003795 chemical substances by application Substances 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 53
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 33
- 150000007523 nucleic acids Chemical class 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 23
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 235000018417 cysteine Nutrition 0.000 claims description 16
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 14
- 102000017578 LAG3 Human genes 0.000 claims description 12
- 101150030213 Lag3 gene Proteins 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 8
- 208000032818 Microsatellite Instability Diseases 0.000 claims description 8
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000033607 mismatch repair Effects 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 210000002865 immune cell Anatomy 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 102000015728 Mucins Human genes 0.000 claims description 4
- 108010063954 Mucins Proteins 0.000 claims description 4
- -1 ONO2231 Chemical compound 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 230000005867 T cell response Effects 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 230000007547 defect Effects 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 229940127121 immunoconjugate Drugs 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 4
- 229950011068 niraparib Drugs 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 claims description 2
- CTLOSZHDGZLOQE-UHFFFAOYSA-N 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione Chemical compound O=C1C2=C3C=4C(OC)=CC=CC=4NC3=C3CCCC3=C2C(=O)N1CN1CCN(C)CC1 CTLOSZHDGZLOQE-UHFFFAOYSA-N 0.000 claims description 2
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims description 2
- HRYKZAKEAVZGJD-UHFFFAOYSA-N 2-methyl-3,5,7,8-tetrahydro-4h-thiopyrano[4,3-d]pyrimidin-4-one Chemical compound C1CSCC2=C1N=C(C)NC2=O HRYKZAKEAVZGJD-UHFFFAOYSA-N 0.000 claims description 2
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 claims description 2
- HYNBNUYQTQIHJK-UHFFFAOYSA-N 4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1CC(OC)CCN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F HYNBNUYQTQIHJK-UHFFFAOYSA-N 0.000 claims description 2
- XJGXCBHXFWBOTN-UHFFFAOYSA-N 4-[[4-fluoro-3-[2-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1CN2N=C(C(F)(F)F)N=C2CN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F XJGXCBHXFWBOTN-UHFFFAOYSA-N 0.000 claims description 2
- JLFSBHQQXIAQEC-UHFFFAOYSA-N 9x5a2qia7c Chemical compound C1=CC(C(=O)NN2)=C3C2=NC(CN2CC4=CC=CC=C4C2)=NC3=C1 JLFSBHQQXIAQEC-UHFFFAOYSA-N 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 2
- 206010064571 Gene mutation Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 2
- 108091092878 Microsatellite Proteins 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 125000000613 asparagine group Chemical class N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000000941 bile Anatomy 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 230000036755 cellular response Effects 0.000 claims description 2
- BWVHYDYUKQEFHG-UHFFFAOYSA-N cep-8983 Chemical compound COC1=CC=CC2=C1C1=C3C(=O)NC(=O)C3=C3CCCC3=C1N2 BWVHYDYUKQEFHG-UHFFFAOYSA-N 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- HAVFFEMDLROBGI-UHFFFAOYSA-N m8926c7ilx Chemical compound C1CC(O)CCN1CC1=CC=C(OC=2C3=C(C(NN=C33)=O)C=CC=2)C3=C1 HAVFFEMDLROBGI-UHFFFAOYSA-N 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- ISGGVCWFTPTHIX-UHFFFAOYSA-N n'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1CCCCN1CC(O)CONC(=N)C1=CC=CN=C1 ISGGVCWFTPTHIX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 210000003101 oviduct Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229950004707 rucaparib Drugs 0.000 claims description 2
- INBJJAFXHQQSRW-STOWLHSFSA-N rucaparib camsylate Chemical compound CC1(C)[C@@H]2CC[C@@]1(CS(O)(=O)=O)C(=O)C2.CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23 INBJJAFXHQQSRW-STOWLHSFSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940121497 sintilimab Drugs 0.000 claims description 2
- 150000003384 small molecules Chemical group 0.000 claims description 2
- 229950007213 spartalizumab Drugs 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims description 2
- 229950011257 veliparib Drugs 0.000 claims description 2
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416131P | 2016-11-01 | 2016-11-01 | |
| US62/416,131 | 2016-11-01 | ||
| US201662427775P | 2016-11-29 | 2016-11-29 | |
| US62/427,775 | 2016-11-29 | ||
| PCT/US2017/059619 WO2018085469A2 (en) | 2016-11-01 | 2017-11-01 | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019537438A JP2019537438A (ja) | 2019-12-26 |
| JP2019537438A5 true JP2019537438A5 (enExample) | 2020-12-17 |
Family
ID=62075645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522850A Withdrawn JP2019537438A (ja) | 2016-11-01 | 2017-11-01 | Ｔｉｍ−３（ｔ細胞イムノグロブリンおよびムチンタンパク質３）に対する抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20190284280A1 (enExample) |
| EP (2) | EP3689419A1 (enExample) |
| JP (1) | JP2019537438A (enExample) |
| KR (1) | KR20190098741A (enExample) |
| CN (1) | CN110062885A (enExample) |
| AU (1) | AU2017354071A1 (enExample) |
| BR (1) | BR112019008861A2 (enExample) |
| CA (1) | CA3041685A1 (enExample) |
| IL (1) | IL266230A (enExample) |
| MA (2) | MA50677A (enExample) |
| MX (1) | MX2019005116A (enExample) |
| SG (2) | SG11201903867YA (enExample) |
| WO (1) | WO2018085469A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN109757103B (zh) | 2016-07-14 | 2024-01-02 | 百时美施贵宝公司 | 针对tim3的抗体及其用途 |
| MX2019005116A (es) | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| JP2019533458A (ja) * | 2016-11-01 | 2019-11-21 | アナプティスバイオ インコーポレイティッド | プログラム死１（ｐｄ−１）に対する抗体 |
| WO2018129553A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELIN BINDING PROTEINS |
| KR20200005662A (ko) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| TWI843707B (zh) | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CN112566936B (zh) | 2018-08-21 | 2024-07-12 | 阿尔伯特爱因斯坦医学院 | 针对人tim-3的单克隆抗体 |
| TWI852940B (zh) | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| JP2022504228A (ja) | 2018-10-03 | 2022-01-13 | テサロ， インコーポレイテッド | ニラパリブ遊離塩基の結晶形態 |
| CN113166071B (zh) | 2018-10-03 | 2025-03-21 | 特沙诺有限公司 | 尼拉帕利盐 |
| AU2019372436A1 (en) * | 2018-11-01 | 2021-05-20 | Merck Patent Gmbh | Methods of administering anti-TIM-3 antibodies |
| WO2020093023A1 (en) * | 2018-11-01 | 2020-05-07 | Merck Patent Gmbh | Anti-tim-3 antibodies |
| KR20210108978A (ko) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| WO2020239558A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021051352A1 (zh) * | 2019-09-19 | 2021-03-25 | 上药生物治疗（香港）有限公司 | 一种分离的抗原结合蛋白及其用途 |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| IL294557A (en) | 2020-01-07 | 2022-09-01 | Univ Texas | Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy |
| CA3169303A1 (en) * | 2020-02-24 | 2021-09-02 | Xiaokun SHEN | Application of poly adp-ribose polymerase inhibitors in corona virus resistance |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| EP4687991A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US6843987B2 (en) | 2000-02-02 | 2005-01-18 | Schering Corporation | Mammalian cytokines; receptors; related reagents and methods |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US20030103985A1 (en) | 2001-05-18 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Cytotoxic CD44 antibody immunoconjugates |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US7470428B2 (en) | 2002-01-30 | 2008-12-30 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| US20030229910A1 (en) | 2002-04-17 | 2003-12-11 | Richard Metz | Short fragment homologous replacement to provide BSE resistant cattle |
| GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| US7824681B2 (en) * | 2005-08-16 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Human monoclonal antibodies that specifically bind IGF-II |
| EP2046833B9 (en) * | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
| MY153248A (en) * | 2006-07-14 | 2015-01-29 | Ac Immune Sa | Humanized antibody against amyloid beta |
| WO2008033333A2 (en) | 2006-09-08 | 2008-03-20 | Amgen Inc. | Il-1 family variants |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| US20090075378A1 (en) | 2007-02-20 | 2009-03-19 | Anaptysbio, Inc. | Somatic hypermutation systems |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| KR101653548B1 (ko) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8012714B2 (en) * | 2008-04-14 | 2011-09-06 | Innovative Targeting Solutions, Inc. | Sequence diversity generation in immunoglobulins |
| KR20110048536A (ko) | 2008-08-28 | 2011-05-11 | 와이어쓰 엘엘씨 | 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도 |
| AU2011262758B8 (en) | 2010-06-11 | 2014-09-04 | Kyowa Kirin Co., Ltd. | Anti-tim-3 antibody |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| CA2843158A1 (en) | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| SI3536710T1 (sl) | 2011-11-16 | 2026-04-30 | Boehringer Ingelheim International Gmbh | Protitelesa proti IL-36R |
| WO2013098420A1 (en) | 2011-12-28 | 2013-07-04 | Immunoqure Ag | Method of isolating human antibodies |
| KR101704893B1 (ko) | 2012-06-15 | 2017-02-08 | 화이자 인코포레이티드 | Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도 |
| WO2014165115A1 (en) | 2013-03-12 | 2014-10-09 | Decimmune Therapeutics, Inc. | Humanized anti-n2 antibodies |
| US9896513B2 (en) * | 2013-03-15 | 2018-02-20 | Novo Nordisk A/S | Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| HUE045065T2 (hu) * | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| SI3215532T1 (sl) * | 2014-11-06 | 2020-02-28 | F. Hoffmann-La Roche Ag | Protitelesa proti TIM3 in postopki uporabe |
| GB201421430D0 (en) | 2014-12-02 | 2015-01-14 | Medimmune Llc | Antibodies to Adam17 and uses thereof |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| NZ775762A (en) | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| PE20181326A1 (es) * | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| AR108377A1 (es) * | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| US11203637B2 (en) | 2016-08-26 | 2021-12-21 | Beigene, Ltd. | Anti-Tim-3 antibodies and use thereof |
| MX2019005116A (es) | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| WO2018129553A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
-
2017
- 2017-11-01 MX MX2019005116A patent/MX2019005116A/es unknown
- 2017-11-01 BR BR112019008861-0A patent/BR112019008861A2/pt not_active IP Right Cessation
- 2017-11-01 EP EP20150611.0A patent/EP3689419A1/en not_active Withdrawn
- 2017-11-01 CN CN201780075954.0A patent/CN110062885A/zh active Pending
- 2017-11-01 SG SG11201903867YA patent/SG11201903867YA/en unknown
- 2017-11-01 SG SG10201913308PA patent/SG10201913308PA/en unknown
- 2017-11-01 AU AU2017354071A patent/AU2017354071A1/en not_active Abandoned
- 2017-11-01 EP EP17867255.6A patent/EP3535586A4/en not_active Withdrawn
- 2017-11-01 CA CA3041685A patent/CA3041685A1/en not_active Abandoned
- 2017-11-01 WO PCT/US2017/059619 patent/WO2018085469A2/en not_active Ceased
- 2017-11-01 US US16/346,463 patent/US20190284280A1/en not_active Abandoned
- 2017-11-01 MA MA050677A patent/MA50677A/fr unknown
- 2017-11-01 MA MA046113A patent/MA46113A/fr unknown
- 2017-11-01 JP JP2019522850A patent/JP2019537438A/ja not_active Withdrawn
- 2017-11-01 KR KR1020197015227A patent/KR20190098741A/ko not_active Ceased
-
2019
- 2019-04-24 IL IL266230A patent/IL266230A/en unknown
-
2021
- 2021-10-27 US US17/512,257 patent/US11753472B2/en active Active
-
2023
- 2023-07-18 US US18/354,395 patent/US20230416368A1/en not_active Abandoned
-
2025
- 2025-02-28 US US19/066,882 patent/US20250368739A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019537438A5 (enExample) | ||
| JP2019533458A5 (enExample) | ||
| Zhang et al. | Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma | |
| US20230115328A1 (en) | Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer | |
| JP2020504141A5 (enExample) | ||
| Song et al. | Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens | |
| JP2020524174A5 (enExample) | ||
| JP2020503364A5 (enExample) | ||
| JP2021515559A5 (enExample) | ||
| JP2017506067A5 (enExample) | ||
| Ouladan et al. | Chimeric antigen receptor-T cells in colorectal cancer: pioneering new avenues in solid tumor immunotherapy | |
| JP2017536099A5 (enExample) | ||
| KR20220007584A (ko) | 항-clec2d 항체 및 이의 사용 방법 | |
| Liu et al. | Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy | |
| FI3464380T3 (fi) | Gp100-spesifisen tcr-anti-cd3 scfv-fuusioproteiinin annosteluohjelma | |
| JP2023522857A5 (enExample) | ||
| Lulla et al. | The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma | |
| JP2023548051A5 (enExample) | ||
| Sun et al. | Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience | |
| JP2023548051A (ja) | 肺がんのためのｌａｇ－３アンタゴニスト療法 | |
| Shademan et al. | CAR T cells: cancer cell surface receptors are the target for cancer therapy | |
| JP2022549273A (ja) | Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング | |
| Wen et al. | Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer | |
| WO2017038997A1 (ja) | Ａｌｌｅｒｇｉｎ－１アンタゴニストによるがん免疫増強剤 | |
| CN119497575A (zh) | 用于现货型免疫疗法的nk细胞产品的冷冻保存 |